Member Info for Big_kahuna

Aptamer Group attending BIO-Europe 2025 (Vienna, 3–5 Nov)

We’ll be at Europe’s biggest biopharma partnering event — where pharma, biotech and investors connect to form new partnerships.

A strong opportunity to raise visibility, open new doors and showcase what APTA can deliver.

Don’t think the MMs care too much — they make their money on buys and sells. This one probably just took a bit longer to marry up, though it does suggest they’re not carrying a lot of stock.

As I mentioned before the MRE, whatever the results the holders will view as positive and in line with drilling, for me the Tin was towards the lower end of what was expected, but we all know there is plenty more in the ground, just need to get it into the updated JORC with more drilling.

I think if I’d have called the MRE results yesterday with today’s announced levels everyone would have said I was calling the tin too low.

I think the drop today is just traders exiting or shorter term holders moving on to more immediate opportunities, fundamentals haven’t changed.

I think we might pierce 7p tomorrow, but I’m happy to potter around this level for now, plenty of catalyst before year end, makes a change from all the other rollercoaster’s I’m on.

Wish I had money to top up, seems half my portfolio needs more funds and I have a watchlist of another 3 or 4 I want a slice of!

Devils in the detail on 1 and 2, but I’d actually argue that to get the best outcome, the company has to act like option (3) — full go-it-alone development — even if that’s not the endgame.

You only attract serious JV or buyout interest once you prove you don’t need them. If management move forward as if they’re building the mine themselves — pilot, recovery data, permitting, engineering — the market starts to price EEE as a potential producer, not a distressed explorer.

That’s what forces a proper valuation.

So yes, JV is probably the most balanced route (and a later buyout likely), but the value only comes if we look like we can and will go solo if needed.

Unfortunately I have zero liquidity and don’t want to rush exit on any other holdings, unless one of my other investments pops tomorrow then I’m going to be hoping we hold the lows for a while.

Would be good timing for Paul and gang to buy some shares, I think I own more than they do.

Are people confusing FDA approval with Opran status, we are a long way from FDA approval.

• Scenario A (ODD granted + positive partnering/licensing deal):

If the FDA grants ODD (which would be an incremental piece of news) and Nuformix announces a licensing deal (say upfront + milestones) for NXP002, the share price could see a moderate “re‐rating” boost. For example, shares might rise by 20-50 % (depending on prior valuation, market sentiment, liquidity) as the company’s risk profile and commercial potential increase.

• Scenario B (ODD granted + successful early clinical data + major licensing or partner):

If in addition to ODD they publish good early data and secure a major partner, the share could rise substantially – perhaps 50-100 % or more — because the pipeline is de-risked and commercial path clearer.

• Scenario C (Full FDA approval):

This is a transformational event. If NXP002 gets FDA approval for IPF/related fibrosis, the share price could move dramatically (potentially multiples above current) provided the market sees the pathway to revenue and profitability. How big depends on the indication size, pricing, competition, and the deal terms. For a rare disease asset with exclusivity, valuations can go high. But there’s no standard multiplier — could be 2-5× or more, or less if issues arise.

• Scenario D (Negative outcome / delay):

On the flip side, if the FDA denies ODD, or trials fail, or commercial prospects look weak, share price could drop significantly (perhaps 30-70 % or more), especially given the speculative nature of the company.

B_positive, you should save that in a notebook, to save retyping, I suspect you will be able to post the same thing for several months as nothing will move.

Took the time to log into HL website today and asked for significantly more than was offered, would imaging every one will be trying a cheeky Oliver Twist.

Ok paps agree on the spot prices, recognition percentage you can I guess you can make the argument, hopefully the market starts to align on that, because this does look a lot like my EEE experience at the moment, but I’m not looking to sell so doesn’t really matter.

You’d have to sell you wife’s/cousin’s wedding ring!

Stage 1

• KoBold drills ≥ 2 000 m (done → 4 153 m completed).

• No equity earned yet; just earns right to proceed.

Stage 2

• KoBold funds total exploration spend up to US $6 million.

• On completion, ownership locks in at:

• KoBold (Mwinilunga) 70 %

• Tertiary Minerals 20 % (fully carried)

• Mwashia Resources 10 %.

• JV company then formed on those percentages.

The maiden MRE confirms a multi-metallic system at Bisie North:

Tin 10.6 kt at about 0.2–1.3 percent Sn

Copper 46.9 kt at 1.45 percent Cu

Zinc 86.2 kt at 2.7 percent Zn

Silver 1.46 Moz at 14 g per tonne

Using spot prices (Tin 25,000 USD per tonne, Copper 8,500 USD, Zinc 2,600 USD, Silver 25 USD per ounce) gives a total in situ value of about 924 million USD.

Applying typical post-maiden recognition levels:

• 0.5 percent recognition = 4.6 million USD (around 3.8 million GBP)

• 1.0 percent recognition = 9.2 million USD (around 7.5 million GBP)

• 2.0 percent recognition = 18.5 million USD (around 15 million GBP)

At a market cap of roughly 18 million GBP, RMR is already valued at around 2 percent of in situ value. That is the high end of normal post-maiden recognition, suggesting the market has priced in the copper-zinc strength but will need tin growth or resource upgrades to move higher.

Tin came in lighter than expected, but the copper and zinc totals give the project real weight. The next step is deeper drilling and resource expansion to support a move beyond the current 2 to 3 percent recognition range.

No bounce coming and you have not been buying

Ask the ai to comp to its predictions as agreed.

Key points:

• The actual tin number (~10.6 kt) is well below my Bear case (~22 kt).

• The actual copper (~46.9 kt) already exceeds my Bear-case estimate for Cu by a wide margin.

• Zinc (86.2 kt) and silver (1.46 Moz) appear as meaningful by-products, which I had treated more conservatively.

• The tonnage is heavily weighted to Mont Agoma for Cu/Zn, and to a smaller tonnage at Kalayi for Sn.

• The tin grade is much lower than I assumed (0.19% Sn at Mont Agoma vs ~1% I expected) which explains the relatively low tin tonnage.

⸻

🔍 Interpretation & Implications

• The MRE confirms a multi-metallic system rather than a pure high-grade tin system (tin is present but at lower grade/tonnage).

• This means that the project’s value proposition shifts: copper + zinc + silver matter significantly, tin alone is smaller than expected.

• The tin part remains early-stage: the 102-260 kt tin exploration target suggests the company sees major upside if deeper/higher-grade tin zones are found.

• From my earlier framing: The result landed below the Bear case for tin, but for copper it’s already better than the lower bound — so the upside is now more hinged on growing tin (and maintaining strong Cu/Zn) rather than simply hitting a tin-tonnage target.

• Investors should now recalibrate: the risk/reward is less about “tin: high grade near surface” and more about “multi-commodity, continuity, depth extension”.

I’m holding 75m but I can’t take the silly ramping much more, gonna stop looking at this board, and I’ll be out before December if management don’t show some progress.

If I add up the billions given in valuation on this board for the ‘assets’.

30b for coal, 5b hydrogen, 20b for our 10% share of a gold mine that is going to be built and operational in 6 months, probably another 5b for blue rock despite the neglect.

Yet the same people making the claims would surely have sold their mud huts by now to buy more.

It’s very sad to ramp to this level.

But let me guess, you have bought no shares despite this incredible news.

Not sure what worries me more for Orcp, there terrible management team feathering their Pakistan political interests or the ridiculous ramping on this board

I’ll take $50m now